ATE255906T1 - Antikörper gegen cd40 - Google Patents

Antikörper gegen cd40

Info

Publication number
ATE255906T1
ATE255906T1 AT94927340T AT94927340T ATE255906T1 AT E255906 T1 ATE255906 T1 AT E255906T1 AT 94927340 T AT94927340 T AT 94927340T AT 94927340 T AT94927340 T AT 94927340T AT E255906 T1 ATE255906 T1 AT E255906T1
Authority
AT
Austria
Prior art keywords
antibodies against
binding
ligand
monoclonal antibodies
specifically bind
Prior art date
Application number
AT94927340T
Other languages
English (en)
Inventor
William C Fanslow Iii
Jodee Zappone
Mark Alderson
Richard J Armitage
Original Assignee
Immunex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunex Corp filed Critical Immunex Corp
Application granted granted Critical
Publication of ATE255906T1 publication Critical patent/ATE255906T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT94927340T 1993-10-01 1994-09-02 Antikörper gegen cd40 ATE255906T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13054193A 1993-10-01 1993-10-01
PCT/US1994/009984 WO1995009653A1 (en) 1993-10-01 1994-09-02 Antibodies to cd40

Publications (1)

Publication Number Publication Date
ATE255906T1 true ATE255906T1 (de) 2003-12-15

Family

ID=22445171

Family Applications (1)

Application Number Title Priority Date Filing Date
AT94927340T ATE255906T1 (de) 1993-10-01 1994-09-02 Antikörper gegen cd40

Country Status (15)

Country Link
US (1) US5801227A (de)
EP (1) EP0724456B1 (de)
JP (1) JP3675819B2 (de)
KR (1) KR960704576A (de)
AT (1) ATE255906T1 (de)
AU (1) AU686230B2 (de)
CA (1) CA2172376C (de)
DE (1) DE69433406T2 (de)
DK (1) DK0724456T3 (de)
ES (1) ES2211884T3 (de)
FI (1) FI961285L (de)
NO (1) NO961151D0 (de)
NZ (1) NZ273504A (de)
PT (1) PT724456E (de)
WO (1) WO1995009653A1 (de)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
PT812206E (pt) * 1995-03-01 2002-11-29 Immunex Corp Proteina de ligacao a cd40 para estimulacao de uma resposta imunitaria
US6340459B1 (en) 1995-12-01 2002-01-22 The Trustees Of Columbia University In The City Of New York Therapeutic applications for the anti-T-BAM (CD40-L) monoclonal antibody 5C8 in the treatment of reperfusion injury in non-transplant recipients
US20020102706A1 (en) * 1997-06-18 2002-08-01 Genentech, Inc. Apo-2DcR
AU740227B2 (en) * 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
WO1999061065A1 (en) * 1998-05-23 1999-12-02 Leiden University Medical Center Cd40 binding molecules and ctl peptides for treating tumors
EP2039368A3 (de) 1999-04-30 2009-04-01 La Jolla Institute For Allergy And Immunology Verfahren zur Vorbeugung der Reaktivierung von latenten Viren und Überwachung der Virenreplikation
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
DE60035057T2 (de) * 1999-10-04 2008-01-31 Novartis Vaccines and Diagnostics, Inc., Emeryville CD40 Antagonist zur Behandlung von Psoriasis
US20020028178A1 (en) * 2000-07-12 2002-03-07 Nabil Hanna Treatment of B cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications
MXPA02007473A (es) * 2000-02-01 2003-09-22 Tanox Inc Moleculas activadoras de celulas presentadoras de antigenos (apc) que se unen a cd40.
WO2001080884A1 (en) * 2000-04-25 2001-11-01 Idec Pharmaceuticals Corporation Intrathecal administration of rituximab for treatment of central nervous system lymphomas
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
WO2001083755A2 (en) * 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2002028481A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
US20030103971A1 (en) * 2001-11-09 2003-06-05 Kandasamy Hariharan Immunoregulatory antibodies and uses thereof
US20020159996A1 (en) * 2001-01-31 2002-10-31 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
US20030211107A1 (en) * 2002-01-31 2003-11-13 Kandasamy Hariharan Use of CD23 antagonists for the treatment of neoplastic disorders
CA2436180C (en) 2001-01-31 2011-11-08 Idec Pharmaceutical Corporation Immunoregulatory antibodies and uses thereof
US20070065436A1 (en) * 2001-01-31 2007-03-22 Biogen Idec Inc. Anti-cd80 antibody having adcc activity for adcc mediated killing of b cell lymphoma cells alone or in combination with other therapies
CA2658221C (en) * 2001-04-27 2012-11-27 Kyowa Kirin Co., Ltd. Anti-cd40 monoclonal antibody
EP1425040A2 (de) * 2001-09-14 2004-06-09 Cytos Biotechnology AG Steigerung der durch virusähnliche partikel hervorgerufenen immunantwort durch in-vivo aktivierung von antigen-präsentierenden zellen
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
US20030180292A1 (en) * 2002-03-14 2003-09-25 Idec Pharmaceuticals Treatment of B cell malignancies using anti-CD40L antibodies in combination with anti-CD20 antibodies and/or chemotherapeutics and radiotherapy
US8277810B2 (en) * 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1680141T3 (da) * 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Fremgangsmåder til terapi til faste tumorer der udtrykker CD40-celleoverfladeantigenet
US20050136055A1 (en) 2003-12-22 2005-06-23 Pfizer Inc CD40 antibody formulation and methods
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
EP1945260B1 (de) * 2005-11-01 2012-10-24 Novartis AG Verwendungen von anti-cd80-antikörpern
WO2007053661A2 (en) * 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
SMP200800064B (it) 2006-04-21 2009-11-06 Novartis Ag Composizioni farmaceutiche di anticorpi anti-cd40 antagonista
WO2007130493A2 (en) * 2006-05-03 2007-11-15 Regents Of The University Of Colorado Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
HUE065915T2 (hu) 2011-03-11 2024-06-28 Beth Israel Deaconess Medical Ct Inc Anti-CD40 antitestek és alkalmazásaik
KR102037432B1 (ko) 2011-04-29 2019-11-27 아펙시젠, 인코포레이티드 항-cd40 항체 및 사용 방법
CA2888763A1 (en) 2012-10-30 2014-05-08 Apexigen, Inc. Anti-cd40 antibodies and methods of use
JP6518917B2 (ja) 2015-05-29 2019-05-29 アッヴィ・インコーポレイテッド 抗cd40抗体およびその使用
WO2017040932A1 (en) 2015-09-04 2017-03-09 Primatope Therapeutics Inc. Humanized anti-cd40 antibodies and uses thereof
PE20181367A1 (es) 2015-09-30 2018-08-27 Janssen Biotech Inc Anticuerpos agonistas que se unen especificamente a cd40 humana y metodos de uso
US11497781B2 (en) 2016-03-10 2022-11-15 Cg Oncology, Inc. Methods of treating bladder cancer by combination therapy comprising the oncolytic adenovirus CG0070 and an immune checkpoint inhibitor
BR112018071307A2 (pt) 2016-04-18 2019-02-26 Celldex Therapeutics, Inc. anticorpos agonistas que ligam cd40 humana e usos dos mesmos
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
WO2018088850A2 (ko) * 2016-11-11 2018-05-17 다이노나(주) Cd40에 특이적으로 결합하는 항체 및 그의 용도
JP2024531480A (ja) 2021-08-26 2024-08-29 デュアリティ バイオロジクス(スーチョウ)カンパニー,リミティド ステロイド化合物及びそのコンジュゲート
US12234294B2 (en) 2021-11-05 2025-02-25 Kiniksa Pharmaceuticals, Gmbh Pharmaceutical composition of a humanized anti-CD40 antibody
WO2025186778A1 (en) 2024-03-08 2025-09-12 Janssen Biotech, Inc. Combinations of oncolytic viruses and immunomodulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5247069A (en) * 1986-06-13 1993-09-21 Oncogen Ligands and methods for augmenting B-cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules

Also Published As

Publication number Publication date
WO1995009653A1 (en) 1995-04-13
CA2172376C (en) 2008-11-18
JP3675819B2 (ja) 2005-07-27
AU686230B2 (en) 1998-02-05
PT724456E (pt) 2004-04-30
DK0724456T3 (da) 2004-04-13
NO961151L (no) 1996-03-21
NO961151D0 (no) 1996-03-21
FI961285A0 (fi) 1996-03-20
DE69433406T2 (de) 2004-10-07
NZ273504A (en) 1997-12-19
EP0724456A1 (de) 1996-08-07
CA2172376A1 (en) 1995-04-13
ES2211884T3 (es) 2004-07-16
KR960704576A (ko) 1996-10-09
US5801227A (en) 1998-09-01
AU7681994A (en) 1995-05-01
EP0724456B1 (de) 2003-12-10
FI961285A7 (fi) 1996-03-20
JPH09504169A (ja) 1997-04-28
DE69433406D1 (de) 2004-01-22
FI961285L (fi) 1996-03-20
EP0724456A4 (de) 1997-07-02

Similar Documents

Publication Publication Date Title
DE69433406T2 (de) Antikörper gegen cd40
DE69429925D1 (de) METHODE ZUR BINDUNG VON MATERIAL AN DAS Beta-AMYLOID-PEPTID
EP1071458A4 (de) Humanisierter antikörper und dessen verwendungen
DE69319662D1 (de) Monoklonale Antikörper gegen GP130-Protein
DE69233735D1 (de) Bindungsdomänen des Delta-proteins
DE69942671D1 (de) Humanisierte antikoerper gegen gamma-interferon
PT941121E (pt) Preparados farmaceuticos liofilizados, estaveis, de anticorpos monoclonais ou policlonais
ATE155818T1 (de) Nicht glycosylierter anti-cd3-igg-antikörper
GB2383331A (en) Monoclonal antibody DS6 Tumor-associated antigen CA6 and methods of use thereof
DK1214292T3 (da) Tyrosinderivater
DK0640135T3 (da) Immunoglobulinbindende proteiner, der er afledt af protein L, og anvendelser af disse
DE69128543D1 (de) Monoklonale antikörper der maus
DE3854502D1 (de) Gegen hiv-antigene spezifischer monoklonaler antikörper.
DE69434384D1 (de) Metalkomplexbildner
DE3482905D1 (de) Monoklonale antikoerper gegen lungenkrebs des "nicht-kleine-zellen"-typs.
DK0812206T3 (da) Fremgangsmåde til stimulering af en immunrespons
DE69535855D1 (de) Calciumbindende rekombinante antikörper gegen protein c
PT840620E (pt) Antagonistas de il-8 para o tratamento de asma
IS6143A (is) Peptíð úr TT veiruröð og einsérhæfð mótefni, sem bindast TT veirunni
DE59608073D1 (de) Antikörper gegen ein, einen histidin-anteil aufweisendes fusionspolypeptid
DE3888604D1 (de) Monoklonale Antikörper gegen Antithrombinbindende Substanz und seine Verwendungen.
DE69409961D1 (de) Triarylethylenderivate zur therapeutischen verwendung
DE3687542D1 (de) Monoklonaler antikoerper gegen humanes protein c.
MX9202642A (es) Anticuerpos monoclonales y antigeno para melanoma humano.
DE68912772D1 (de) Monoklonaler antikörper gegen entero-viren.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0724456

Country of ref document: EP

REN Ceased due to non-payment of the annual fee